WilliamAWegenerMD

Nuclear Medicine • Broomall, PA

Physician

Join to view full profile

Are you Dr. Wegener?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 28 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
22 Stanfield Ave
Broomall, PA 19008
Phone+1 610-353-4738

Summary

Dr. William Wegener, MD is a board certified nuclear medicine physician in Broomall, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania and New Jersey.

Education & Training

Drexel University College of Medicine/Hahnemann University HospitalResidency, Radiology-Diagnostic, 1990 - 1991
University of Pennsylvania Health SystemResidency, Nuclear Medicine, 1988 - 1990
Drexel University College of Medicine/Hahnemann University HospitalInternship, Internal Medicine, 1987 - 1988
University of Miami Leonard M. Miller School of MedicineClass of 1987

Certifications & Licensure

PA State Medical License 1990 - 2024
NJ State Medical License 2002 - 2019
American Board of Nuclear Medicine Nuclear Medicine

Clinical Trials

Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Start of enrollment: 1997 Mar 01
Unknown status
Phase 3
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Start of enrollment: 1997 Mar 01
Unknown status
Phase 2, Phase 3
Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Start of enrollment: 2000 Jan 01
Completed
Phase 1, Phase 2
Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer Start of enrollment: 2000 Jan 01
Completed
Phase 1, Phase 2
Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG Start of enrollment: 2000 Aug 01
Completed
Phase 1, Phase 2
Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma Start of enrollment: 2004 Sep 01
Completed
Phase 1, Phase 2
Safety Study of NHL With 90Y-hLL2 IgG Start of enrollment: 2002 Aug 01
Completed
Phase 1, Phase 2
Phase I/II Study of hLL1 in Multiple Myeloma Start of enrollment: 2007 Jan 01
Completed
Phase 1, Phase 2
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL Start of enrollment: 2008 Jan 01
Completed
Phase 1, Phase 2
Study of Veltuzumab (hA20) at Different Doses in Patients With ITP Start of enrollment: 2007 Nov 01
Terminated
Phase 1, Phase 2
Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma Start of enrollment: 2004 Mar 01
Completed
Phase 1, Phase 2
Safety and Efficacy Study of 90Y-hPAM4 at Different Doses Start of enrollment: 2004 Aug 01
Completed
Phase 1, Phase 2
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL Start of enrollment: 2008 Aug 01
Completed
Phase 1, Phase 2
Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer Start of enrollment: 2008 Jan 01
Completed
Phase 1, Phase 2
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies. Start of enrollment: 2012 Mar 01
Withdrawn
Phase 1
Join now to see all

Publications & Presentations

PubMed

99 citations
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
Kevin Kalinsky, Jennifer R. Diamond, Linda T. Vahdat, Sara M. Tolaney, Dejan Juric
Annals of Oncology. 2020-12-01
480 citations
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff
The New England Journal of Medicine. 2019-02-20
48 citations
Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the ...
Jacques-Eric Gottenberg, Thomas Dörner, Hendrika Bootsma, Valérie Devauchelle-Pensec, Simon J. Bowman
Arthritis & Rheumatology. 2018-04-12